Hengrui Medicine (01276.HK): The National Medical Products Administration conditionally approved the launch of the innovative class 1 drug apple acid famitinib capsules.

Zhixin Finance APP News, CSPC Pharmaceutical Group Limited (01276.HK) announced that recently, the company and its subsidiary, Suzhou Shengdia Biopharmaceutical Co., Ltd., received a notice from the National Medical Products Administration, conditionally approving the listing of the company's Class 1 innovative drug, Apatinib Mesylate Capsules, and the combination of Carlotinib Monoclonal Antibody for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with Bevacizumab Monoclonal Antibody.